卡马替尼

卡马替尼（CAS 1029712-80-8）的公开数据库记录，列此仅供独立核对。

危险化学品分类与危害说明

这个物质在各数据库里的编号

数据库记载的用途

• In the US, capmatinib is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test. Capmatinib is approved to treat adults with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping alterations in Canada.
• Capmatinib is an orally available, small molecule inhibitor of the mesenchymal-epithelial transition (MET) factor tyrosine kinase receptor that is used in selected patients with non-small cell lung cancer (NSCLC). Serum aminotransferase elevations are common during therapy with capmatinib, which rarely can lead to clinically apparent liver injury that can be severe and even fatal.
• Breast Feeding; Lactation; Milk, Human; Enzyme Inhibitors; Protein Kinase Inhibitors; Signal Transduction Inhibitors
• Take with or without food. Co-administration with high-fat meals slightly alters AUC, but not to a clinically significant extent.
• Established Pharmacologic Class [EPC] - Kinase Inhibitor
• Mechanisms of Action [MoA] - Mesenchymal Epithelial Transition Inhibitors

它在各数据库里的别名

capmatinib; 1029712-80-8; INCB28060; INC-280; 2-fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide; INCB-28060; NVP-INC280-NX; INCB 28060; NVP-INC280; TY34L4F9OZ; 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide; INCB-28060 FREE BASE; DTXSID90145595; 2-fluoro-N-methyl-4-{7-[(quinolin-6-yl)methyl]imidazo[1,2-b][1,2,4]triazin-2-yl}benzamide; 2-fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo(1,2-b)(1,2,4)triazin-2-yl)benzamide; capmatinibum

计算机算出的分子描述符

数据库摘要

Capmatinib · CAS 1029712-80-8 · C23H17FN6O. UNII TY34L4F9OZ.

数据来源：PubChem / Wikidata；与随货 COA 不一致时以 COA 为准。